Almahmeed Wael, Alabadla Zainab, Al Awadi Fatheya, Alrohmaihi Dalal, AlShamiri Mostafa, Elbadawi Hussein, El-Tamimi Hassan, Elzouki Abdel-Nasser, Farghaly Mohamed, Hafidh Khadija, Hassanein Mohamed, Hamad Adel Khalifa, Khunti Kamlesh, Sabbour Hani, Schutte Aletta E
Cleveland Clinic Abu Dhabi, Hamouda Bin Ali Al Dhaheri Street, Abu Dhabi, United Arab Emirates.
Diabetes and Endocrine Department, Al Jalila Children's Hospital, Dubai, United Arab Emirates.
Adv Ther. 2025 Mar;42(3):1340-1359. doi: 10.1007/s12325-024-03103-5. Epub 2025 Jan 22.
Hypertension, dyslipidemia, and type 2 diabetes are highly prevalent and poorly controlled cardiometabolic diseases in the Middle East. Therapeutic non-adherence and therapeutic inertia are major contributors to this suboptimal disease control. Regardless of the cardiometabolic disease, evidence-based solutions may be used to improve therapeutic non-adherence and overcome inertia, and thereby help to alleviate the heavy burden of cardiovascular disease in the Middle East. Such solutions include the routine and early use of single-pill combinations, educational initiatives for patients, and multidisciplinary team-based care. This article highlights these and other potential solutions for therapeutic non-adherence and inertia, as discussed at the 2024 Evidence in the Cardiometabolic Environment (EVIDENT) Summit. There is now a 'call-to-action' from healthcare providers and other stakeholder groups to ensure that the solutions discussed at this meeting are implemented within health systems in the Middle East to significantly improve cardiovascular outcomes.Infographic available for this article.
高血压、血脂异常和2型糖尿病在中东地区是高度流行且控制不佳的心脏代谢疾病。治疗不依从和治疗惰性是导致这种疾病控制不佳的主要因素。无论哪种心脏代谢疾病，基于证据的解决方案都可用于改善治疗不依从并克服惰性，从而有助于减轻中东地区心血管疾病的沉重负担。此类解决方案包括常规和早期使用单片复方制剂、针对患者的教育举措以及基于多学科团队的护理。本文重点介绍了这些以及其他针对治疗不依从和惰性的潜在解决方案，这些内容在2024年心脏代谢环境证据（EVIDENT）峰会上进行了讨论。现在，医疗保健提供者和其他利益相关者团体发出了“行动呼吁”，以确保本次会议讨论的解决方案在中东地区的卫生系统中得到实施，从而显著改善心血管疾病的治疗效果。本文配有信息图。
